Salud financiera de hoja de balance de Editas Medicine
Salud financiera controles de criterios 6/6
Editas Medicine tiene un patrimonio de los accionistas total de $349.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $499.2M y $150.1M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$323.11m |
| Patrimonio | US$349.10m |
| Total pasivo | US$150.06m |
| Activos totales | US$499.15m |
Actualizaciones recientes sobre salud financiera
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12Recent updates
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Editas: Gene Therapy Specialist Leading The Way In Eye Disease
Aug 27Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($340.8M) de EDIT superan a sus pasivos a corto plazo ($63.2M).
Pasivo a largo plazo: Los activos a corto plazo de EDIT ($340.8M) superan a sus pasivos a largo plazo ($86.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: EDIT está libre de deudas.
Reducción de la deuda: EDIT no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: EDIT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: EDIT dispone de suficiente cash runway para 1.6 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 19.2% cada año.